Citius Pharmaceuticals Inc (CTXR)

0.3657 -0.02 (-5.19%) USD  |  NASDAQ  |  Nov 14, 12:39
More

Citius Pharmaceuticals Research and Development Expense (Quarterly): 2.764M for June 30, 2024

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2013. Upgrade now.
Date Value
June 30, 2024 2.764M
March 31, 2024 3.606M
December 31, 2023 2.622M
September 30, 2023 2.883M
June 30, 2023 3.765M
March 31, 2023 4.727M
December 31, 2022 3.446M
September 30, 2022 3.857M
June 30, 2022 4.888M
March 31, 2022 3.452M
December 31, 2021 5.458M
September 30, 2021 2.294M
June 30, 2021 2.204M
March 31, 2021 1.551M
December 31, 2020 6.191M
September 30, 2020 1.488M
June 30, 2020 2.644M
March 31, 2020 2.016M
December 31, 2019 2.664M
September 30, 2019 2.018M
June 30, 2019 2.766M
Date Value
March 31, 2019 1.700M
December 31, 2018 2.113M
September 30, 2018 1.738M
June 30, 2018 0.7789M
March 31, 2018 3.440M
December 31, 2017 0.6065M
September 30, 2017 0.4745M
June 30, 2017 0.1906M
March 31, 2017 0.8599M
December 31, 2016 1.411M
September 30, 2016 1.923M
June 30, 2016 0.3811M
March 31, 2016 -0.2003M
December 31, 2015 0.8292M
September 30, 2015 0.6222M
June 30, 2015 0.4155M
March 31, 2015 0.2822M
December 31, 2014 0.4771M
June 30, 2014 0.00
March 31, 2014 0.00
December 31, 2013 0.4374M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

1.488M
Minimum
Sep 2020
6.191M
Maximum
Dec 2020
3.290M
Average
2.883M
Median
Sep 2023

Research and Development Expense (Quarterly) Benchmarks

Agilent Technologies Inc 127.00M
Seelos Therapeutics Inc 0.966M
Cara Therapeutics Inc 9.308M
Moleculin Biotech Inc 4.09M
Citius Oncology Inc --